Vivek Subbiah: Consensus Statement on Molecular Tumor Boards from IASLC
Vivek Subbiah, Chief, Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn:
“New paper alert Pleased to share our paper on ‘Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer’.
Kudos to the amazing Mihaela Aldea for integrating so many inputs (just look at the author list, has so many awesome colleagues in Lung Cancer Precision Oncology).
This paper shapes a framework that goes beyond lung cancer-standardizing Precision Medicine across tumor types.”
Title: Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer
Authors: Mihaela Aldea, Julia K. Rotow, Maria Arcila, Matthew Hatton, Lynette Sholl, Christian Rolfo, Marco Tagliamento, Teodora Radonic, Kurt A. Schalper, Vivek Subbiah, Umberto Malapelle, Anja C. Roden, Rami Manochakian, Ming-Sound Tsao, Helena Linardou, Rina Hui, Silvia Novello,Alastair Greystoke, Anjali Saqi, Sylvie Lantuejoul, David M. Hwang, Kelly Nevins, Murry Wynes, Saiama Waqar, Yuchen Han, Yasushi Yatabe, Wei-Chin Chang, Takuo Hayashi, Tae-Jung Kim, Paul Hofman, Fabio Tavora, Fred R. Hirsch, Valeria Denninghoff, Natasha B. Leighl, Alexander Drilon, Wendy A. Cooper, Sanja Dacic, Pranshu Mohindra, Nick Pavlakis, Fernando Lopez-Rios.
Read the Full Article at Journal of Thoracic Oncology.
More posts featuring Vivek Subbiah on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023